Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Dyne Therapeutics, Inc. DYN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$37.60
+89.8%

Dyne Therapeutics, Inc. (DYN) is a Biotechnology company in the Healthcare sector, currently trading at $19.81. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is DYN = $38 (+89.8% upside).

Valuation: DYN trades at a trailing Price-to-Earnings (P/E) of -5.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.53.

Net income is $446M (loss), growing at -39.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $20M against $972M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 22.25 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $1.2B.

Analyst outlook: 12 / 13 analysts rate DYN as buy (92%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$37.60
▲ 89.8% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Dyne Therapeutics, Inc., the average price target is $37.60, with a high forecast of $60.00, and a low forecast of $23.00.
Highest Price Target
$60.00
Average Price Target
$37.60
Lowest Price Target
$23.00

DYN SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 62/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DYN

✓
VALUE Pass
62/100
DYN trades at a trailing Price-to-Earnings (P/E) of -5.3 (S&P 500 average ~25). Forward PEG 2.53 — overvalued. Analyst consensus target is $38, implying +91.8% from the current price $20. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
DYN: +0%/yr revenue is, -39.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet DYN: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 22.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
DYN: Gross margin is 0% (+0 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 12 / 13 analysts rate DYN as buy (92%). Analyst consensus target is $38 (+91.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range6.36-25
Volume1.96M
Avg Volume (30D)2.13M
Market Cap$3.27B
Beta (1Y)1.29
Share Statistics
EPS (TTM)-3.47
Shares Outstanding$128.44M
IPO Date2020-09-17
Employees192
CEOJohn G. Cox
Financial Highlights & Ratios
Gross Profit$-2.05M
EBITDA$-437.97M
Net Income$-446.21M
Operating Income$-468.18M
Total Cash$1.11B
Total Debt$20.28M
Net Debt$-873.09M
Total Assets$1.19B
Price / Earnings (P/E)-5.7
Analyst Forecast
1Y Price Target$38.50
Target High$60.00
Target Low$23.00
Upside+94.3%
Rating ConsensusBuy
Analysts Covering13
Buy 92% Hold 8% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS26818M1080

Price Chart

Track all markets on TradingView
DYN
Dyne Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
6.36 52WK RANGE 25.00

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 CYTK
CYTK
Cytokinetics, Incorporated
$66.35
-0.55%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message